Payment overview · 2025
General Payments
$261.26
14 reported records · 9 companies
Healthcare provider profile · identity verified
Robert L Rosin, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ULYSSES, KS · NPI 1124058755
Verified facts
What the public records show
CMS Open Payments records show Robert L Rosin, MD received $261.26 in general payments during 2025 across 14 reported records.
Amgen Inc. accounted for 18.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.80 | 18.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.29 | 16.9% | 3 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.28 | 12.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.44 | 11.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.20 | 10.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.30 | 8.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.37 | 7.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.90 | 7.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $18.68 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $261.26 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $44.29 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.61 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.61 | 2 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $32.28 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.44 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.44 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.20 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 515 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 341 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 321 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 271 | 79 |
| Losartan Potassium | Losartan Potassium | 222 | 70 |
| Potassium Chloride | Potassium Chloride | 210 | 63 |
| Eliquis | Apixaban | 173 | 34 |
| Lisinopril | Lisinopril | 172 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 42 |
| Warfarin Sodium | Warfarin Sodium | 148 | 13 |
| Gabapentin | Gabapentin | 144 | 33 |
| Pregabalin | Pregabalin | 142 | 21 |
| Metformin Hcl | Metformin Hcl | 124 | 43 |
| Furosemide | Furosemide | 121 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 34 |
| Allopurinol | Allopurinol | 111 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 32 |
| Celecoxib | Celecoxib | 106 | 25 |
| Simvastatin | Simvastatin | 104 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 27 |
| Montelukast Sodium | Montelukast Sodium | 101 | 26 |
| Tramadol Hcl | Tramadol Hcl | 98 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 90 | 29 |
| Carvedilol | Carvedilol | 85 | 29 |
| Meloxicam | Meloxicam | 82 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 79 | 16 |
| Omeprazole | Omeprazole | 79 | 30 |
| Ozempic | Semaglutide | 79 | suppressed |
| Clonazepam | Clonazepam | 75 | suppressed |
| Mirtazapine | Mirtazapine | 75 | 13 |
| Trazodone Hcl | Trazodone Hcl | 72 | 14 |
| Famotidine | Famotidine | 70 | 15 |
| Januvia | Sitagliptin Phosphate | 65 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 64 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 17 |
| Sertraline Hcl | Sertraline Hcl | 61 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 18 |
| Finasteride | Finasteride | 58 | 16 |
| Bumetanide | Bumetanide | 56 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 13 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 52 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | suppressed |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 13 |
| Cephalexin | Cephalexin | 42 | 19 |
| Glipizide | Glipizide | 41 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 37 | 13 |
| Baclofen | Baclofen | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Prednisone | Prednisone | 34 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | 15 |
| Sucralfate | Sucralfate | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | 12 |
| Alprazolam | Alprazolam | 29 | 11 |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 25 |
| Atenolol | Atenolol | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Ondansetron Odt | Ondansetron | 18 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Budesonide | Budesonide | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Irbesartan | Irbesartan | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $261.26 · 14 records | Amgen Inc. | EVENITY, GEMTESA, GIVLAARI, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Omnipod, REPATHA, VRAYLAR, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error